On the allosteric puzzle and pocket crosstalk through computational means.

Allostery is a constitutive, albeit often elusive, feature of biomolecular systems, which heavily determines their functioning. Its mechanical, entropic, long-range, ligand, and environment-dependent nature creates far from trivial interplays between residues and, in general, the secondary structure of proteins. This intricate scenario is mirrored in computational terms as different notions of "correlation" among residues and pockets can lead to different conclusions and outcomes. In this article, we put on a common ground and challenge three computational approaches for the correlation estimation task and apply them to three diverse targets of pharmaceutical interest: the androgen A2A receptor, the androgen receptor, and the EGFR kinase domain. Results show that partial results consensus can be attained, yet different notions lead to pointing the attention to different pockets and communications.

Probabilistic Pocket Druggability Prediction via One-Class Learning.

The choice of target pocket is a key step in a drug discovery campaign. This step can be supported by in silico druggability prediction. In the literature, druggability prediction is often approached as a two-class classification task that distinguishes between druggable and non-druggable (or less druggable) pockets (or voxels). Apart from obvious cases, however, the non-druggable class is conceptually ambiguous. This is because any pocket (or target) is only non-druggable until a drug is found for it. It is therefore more appropriate to adopt a one-class approach, which uses only unambiguous information, namely, druggable pockets. Here, we propose using the import vector domain description (IVDD) algorithm to support this task. IVDD is a one-class probabilistic kernel machine that we previously introduced. To feed the algorithm, we use customized DrugPred descriptors computed via NanoShaper. Our results demonstrate the feasibility and effectiveness of the approach. In particular, we can remove or mitigate biases chiefly due to the labeling.

Computational drug discovery under RNA times.

RNA molecules play many functional and regulatory roles in cells, and hence, have gained considerable traction in recent times as therapeutic interventions. Within drug discovery, structure-based approaches have successfully identified potent and selective small-molecule modulators of pharmaceutically relevant protein targets. Here, we embrace the perspective of computational chemists who use these traditional approaches, and we discuss the challenges of extending these methods to target RNA molecules. In particular, we focus on recognition between RNA and small-molecule binders, on selectivity, and on the expected properties of RNA ligands.